Innovation, Science and Economic Development Canada
Feds Back AI-Driven Cell & Gene Therapy Production
OmniaBio’s expanded facility in Hamilton seeks to drive a 5X increase in manufacturing efficiency while reducing production and supply costs by up to 50%, facilitating patient access to life-saving treatments for chronic diseases, including cancer
The Government of Canada is working tirelessly to build up Canada’s life sciences and biomanufacturing sector to develop safe and effective next-generation treatments. Since March 2020, over $2.3 billion has been invested to rebuild Canada’s vaccines, therapeutics and biomanufacturing capacity across our country.
Today, the Honourable Anita Anand, Minister of Innovation, Science and Industry, announced that Canada will work with OmniaBio to expand its facility to manufacture cell and gene therapies and provide production services to companies around the world, strengthening Canada’s participation in global value chains. Cell and gene therapies have the potential to revolutionize the treatment of a broad range of life-threatening diseases.
OmniaBio’s project will be focusing primarily on advanced treatments for chronic diseases, including cancer, autoimmune conditions, diabetes, and cardiovascular and neurological diseases. OmniaBio is seeking to expand its current space at the McMaster Innovation Park facility in Hamilton, Ontario, and invest in artificial intelligence- and robotics-enabled clinical and commercial scale manufacturing.
This groundbreaking project aligns with Canada’s Biomanufacturing and Life Sciences Strategy and will enhance Canada’s leadership position and expertise in this emerging technology area, for the benefit of all Canadians.
https://www.canada.ca/en/innovation-science-economic-development/news/2025/03/federal-government-announces-support-for-cutting-edge-ai–and-robotics-enabled-cell-and-gene-therapy-manufacturing.html